C Ray Therapeutics Highlights Actinium-225 Supply Chain Strategy Around XDC 2026

According to a recent LinkedIn post from C Ray Therapeutics, the company is using the upcoming XDC Conference 2026 in Chengdu to spotlight constraints in the Actinium‑225 supply chain for targeted alpha therapies and a potential path to industrial scale. The post underscores how limited Ac‑225 availability can stall otherwise promising radiopharmaceutical programs in what it calls a “valuation valley” between strong clinical data and commercial viability.

The LinkedIn post highlights NorthStar Medical Radioisotopes’ planned presentation, which is described as outlining a blueprint for securing and scaling global Ac‑225 supply. NorthStar is portrayed as leveraging a single‑campus model that co‑locates commercial‑scale radioisotope production, including Ac‑225 and Cu‑67, with radiopharmaceutical CDMO services to reduce decay losses and logistical risk along the supply chain.

According to the post, NorthStar’s model is positioned around the idea that every mile an isotope travels reduces usable dose, and the company promotes what it calls a “zero decay tax” between production and formulation. The post also notes that NorthStar’s platform is already supporting radioantibody programs from preclinical through late‑stage development and includes Cu‑67 capabilities for theranostic applications that require matched imaging and therapy pairs.

As shared in the post, C Ray Therapeutics serves as co‑organizer of the International RDC Sub‑Forum at XDC 2026 and positions itself as a strategic bridge between NorthStar’s U.S. infrastructure and radiopharmaceutical manufacturing in Asia. The planned connection from NorthStar’s Beloit campus to formulation suites in Chengdu is presented as a step toward a more integrated supply‑to‑CDMO chain aimed at minimizing decay and improving reliability for global radiopharma developers.

For investors, the post suggests that solving Ac‑225 supply constraints may be a key enabler for scaling targeted alpha therapies from clinical promise to commercial reality. C Ray Therapeutics’ role in convening ecosystem players and linking U.S. isotope production with Asian manufacturing capacity could enhance its strategic relevance in the radiopharmaceutical value chain, potentially supporting long‑term partnership opportunities and positioning within a growing nuclear medicine market.